Foundayo (orforglipron) is a once-daily GLP-1 tablet with a dose ladder printed on its FDA label, and the milligram numbers on that label do not match the numbers in the trial papers. That mismatch drives most of the confusion online. This guide puts the label schedule first, maps every trial capsule dose to its tablet strength, tables each major trial, and then covers the vial and powder protocols that circulate for a drug that has only ever been studied and approved as something you swallow.
Ask PeptideBlog about any peptide
Quick answer: On the FDA label, Foundayo starts at 0.8 mg once daily. After at least 30 days it goes to 2.5 mg, then to 5.5 mg after at least 30 more, and then to 9, 14.5 or 17.2 mg based on response and tolerability, with at least 30 days on each step. The maximum is 17.2 mg once daily, taken with or without food and swallowed whole.[1] The trial papers describe the same steps as capsules of 1, 3, 6, 12, 24 and 36 mg, and Lilly says capsules and tablets are not substitutable milligram for milligram.[2] More background is on the orforglipron research entry.
Figures on this page summarize amounts and schedules reported in published research, prescribing information or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported orforglipron amount at a glance
One table, four kinds of rows. The first two are the FDA label. The next group is the human trials, where the doses are mostly capsules. The last group is the non-label material people search for, each tagged with how good its source is. Read the Amount column with one rule in mind: a milligram of trial capsule and a milligram of approved tablet are not the same amount of dose.
Swipe the table sideways to see every column.
| Source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Foundayo label, weight management | Adults with obesity, or overweight plus at least one weight-related condition | Oral tablet | Start 0.8 mg, then 2.5 mg, then 5.5 mg, then 9, 14.5 or 17.2 mg based on response and tolerability. Maximum 17.2 mg. | Once daily | At least 30 days on each step | Prescribing information (label)[1] |
| Foundayo label, with strong CYP3A4 inhibitors | Same adults taking such a drug | Oral tablet | Maximum 9 mg | Once daily | Not applicable | Prescribing information (label)[1] |
| Phase 1a, first-in-human | 92 healthy adults | Oral | Single doses 0.3 to 6 mg; daily doses escalated weekly to final targets of 2 to 24 mg | Single dose, or once daily | 4 weeks of daily dosing | Published human clinical trial (Tier 1)[11] |
| Phase 1 tablet and capsule bioequivalence | 429 healthy adults with obesity or overweight | Oral | Capsules 1, 3, 6, 12, 24, 36 mg and tablets 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg | Once daily | 7 days per strength, fasted | Published human clinical trial (Tier 1)[12] |
| Phase 2, obesity | 272 adults with obesity, or overweight plus a condition, no diabetes | Oral capsule | 12, 24, 36 and 45 mg | Once daily | 36 weeks | Published human clinical trial (Tier 1)[8][9] |
| Phase 2, type 2 diabetes | 383 adults with type 2 diabetes | Oral | 3, 12, 24, 36 (two escalation regimens) and 45 mg (two regimens), versus placebo or dulaglutide 1.5 mg weekly | Once daily | 26 weeks | Published human clinical trial (Tier 1)[10] |
| ATTAIN-1 | 3,127 adults with obesity or overweight plus a condition, no diabetes | Oral capsule | 6, 12 and 36 mg (label equivalents 5.5, 9 and 17.2 mg tablets). Start 1 mg, 4 week steps. | Once daily | 72 weeks | Published human clinical trial (Tier 1)[5][7] |
| ATTAIN-2 | 1,613 adults with obesity or overweight and type 2 diabetes | Oral capsule | 6, 12 and 36 mg (5.5, 9 and 17.2 mg tablets) | Once daily | 72 weeks | Published human clinical trial (Tier 1)[6] |
| ATTAIN-MAINTAIN | 376 adults previously treated with tirzepatide or semaglutide | Oral | Lilly says start 12 mg, raise every 4 weeks to a maximum tolerated 24 or 36 mg; the journal abstract gives no milligram figure | Once daily | 52 weeks | Published human clinical trial (Tier 1)[19][20] |
| ACHIEVE-1 | 559 adults with early type 2 diabetes on diet and exercise | Oral capsule | 3, 12 and 36 mg (2.5, 9 and 17.2 mg tablets) | Once daily | 40 weeks | Published human clinical trial (Tier 1)[13] |
| ACHIEVE-2 | 962 adults with type 2 diabetes on metformin | Oral capsule | 3, 12 and 36 mg, versus dapagliflozin 10 mg | Once daily | 40 weeks | Published human clinical trial (Tier 1)[14] |
| ACHIEVE-3 | 1,698 adults with type 2 diabetes on metformin | Oral capsule | 12 and 36 mg, versus oral semaglutide 7 and 14 mg | Once daily | 52 weeks | Published human clinical trial (Tier 1)[15] |
| ACHIEVE-4 | 2,749 adults with type 2 diabetes at higher cardiovascular risk | Oral | Maximum tolerated dose up to 36 mg capsule, which the abstract equates to 17.2 mg tablet; versus insulin glargine | Once daily | Median follow-up 2 years | Published human clinical trial (Tier 1)[16][21] |
| ACHIEVE-5 | 546 adults with type 2 diabetes on insulin glargine | Oral capsule | 3, 12 and 36 mg or placebo, added to insulin glargine | Once daily | 40 weeks | Published human clinical trial (Tier 1)[17] |
| ACHIEVE-J | 401 Japanese adults with type 2 diabetes | Oral | 3, 12 and 36 mg | Once daily | 52 weeks (safety) | Published human clinical trial (Tier 1)[18] |
| Online “dosing calculators” | No trial population | Subcutaneous, as the pages state, although the same pages call the drug an oral capsule | Default 6 mg; “research range” 6 to 12 mg; chart of 3, 6, 9 and 12 mg | Once daily | Reconstituted vial used within 28 days | Community, vendor or clinic reported (Tier 6); origin unclear[30][31][32] |
| Offers reported on a counterfeit pharmacy site | Online buyers | Not stated | Listed as 3, 12, 24 and 36 mg | Not stated | Not stated | Community, vendor or clinic reported (Tier 6); counterfeit, per a domain-intelligence report[29] |
| “Research use” seller pages | Not applicable | Not stated | Quantities and concentrations “deliberately not given” | Not stated | Not stated | Community, vendor or clinic reported (Tier 6); vendor reported[34] |
| Weight-based dosing (mg per kg) | Not applicable | Not applicable | None on the label; doses are fixed milligram amounts | Not applicable | Not applicable | Prescribing information (label)[1] |
Trial sizes are as randomized or treated in each paper. ATTAIN-1 and ATTAIN-2 are called Trial 1 and Trial 2 on the label.[1] The label does not say whether its trial doses were capsules or tablets; it describes an investigational formulation and shows the equivalent Foundayo doses.[1] The 45 mg capsule arm of the Phase 2 obesity trial has no tablet equivalent in Lilly’s table.[2][8]
Where these figures come from
Nearly every orforglipron number online traces to one of three places: the label, the Phase 3 papers, or a calculator page that copied trial arms without a reference list.
- Most-reported figure: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg once daily, 30 days minimum per step, 17.2 mg maximum. Its origin is Lilly’s label.[1] The trials used a 4 week step with capsule equivalents of the same ladder, starting at 1 mg.[7]
- Second most-reported set: 6, 12 and 36 mg. These are the ATTAIN-1 and ATTAIN-2 capsule arms, and they are not label strengths.[5][6]
- Human evidence: strong for the 6, 12 and 36 mg capsule arms over 72 weeks in obesity, and for 3, 12 and 36 mg over 26 to 52 weeks in type 2 diabetes. Nothing above 36 mg capsule has a Phase 3 result. The 45 mg capsule appears only in the Phase 2 trials.[5][6][8][10][13]
- Animal evidence: the abstracts I opened give no per-kilogram amounts, and the label says orforglipron is not pharmacologically active in rats or mice, so rodent doses mean little for people.[1][22][23]
- Practitioner figures: I found no practitioner commentary with orforglipron amounts that is independent of the label and trials.
- Community and vendor figures: a wiki publishes vial calculators with a default of 6 mg once daily injected under the skin and a “research range” of 6 to 12 mg. Its own community page lists zero reports and links two subreddit home pages. Seller pages say quantities are deliberately not given.[30][31][32][33][34]
- Websites repeating each other: the wiki pages repeat the trial names and arm sizes, cite no papers, and disagree with themselves about whether the drug is oral or injected.[30][31][32] Agreement on vial arithmetic only means the division is right.
- Weight-based conversions: none. The label uses fixed milligram strengths and the trials gave the same doses regardless of body weight.[1][5]
Detailed human data
What the label says, as written
The Foundayo prescribing information was revised in July 2026.[1] Approval came on 1 April 2026.[3][4] The label indicates the drug, “in combination with a reduced-calorie diet and increased physical activity,” to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or with overweight plus at least one weight-related comorbid condition.[1]
Swipe the table sideways to see every column.
| Item | What the label says |
|---|---|
| Starting dose | 0.8 mg by mouth once daily.[1] |
| Step interval | At least 30 days on the current dose before each increase.[1] |
| Second and third steps | 2.5 mg, then 5.5 mg, once daily.[1] |
| Later steps | 9 mg, 14.5 mg or 17.2 mg once daily, based on response and tolerability. The sections I read give no further criteria for choosing among them.[1] |
| Maximum | 17.2 mg once daily.[1] |
| How to take it | Once daily with or without food. Swallow the tablet whole; do not break, crush or chew it. No more than one tablet per day.[1] |
| Missed dose | Take it as soon as possible and do not double the next dose. After 7 or more consecutive missed doses, restart dose escalation at a lower dosage.[1] |
| Strong CYP3A4 inhibitors | Avoid those that also inhibit OATP1B (ritonavir is the example given). Otherwise the maximum is 9 mg once daily.[1] |
| CYP3A4 inducers | Avoid strong inducers. With moderate inducers, monitor effectiveness and escalate as needed.[1] |
| Kidney and liver | No adjustment for kidney impairment. No dose change for mild or moderate liver impairment; not recommended in severe impairment (Child-Pugh C).[1] |
| Weight-based dose | None. Fixed milligram strengths.[1] |
The label lists six tablet strengths: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg.[1] The sections I read name no maximum treatment duration and give no conversion from any injectable GLP-1 drug.[1]
The Foundayo dose chart, as the label allows it
This month-by-month chart is built from the label rule: the earliest day each strength can start if every strength is used in order and held for exactly the 30 day minimum. The label sets a floor, not a timetable, and its fourth step lists 9, 14.5 and 17.2 mg together without saying whether any may be skipped.[1]
Swipe the table sideways to see every column.
| Strength | Earliest start | Position on the label |
|---|---|---|
| 0.8 mg | Day 1 | Starting dose[1] |
| 2.5 mg | Day 31 | Second step[1] |
| 5.5 mg | Day 61 | Third step[1] |
| 9 mg | Day 91 | Fourth-step option[1] |
| 14.5 mg | Day 121 | Fourth-step option[1] |
| 17.2 mg | Day 151 | Fourth-step option and maximum[1] |
Passing through all six strengths takes at least 150 days, about five months. The ATTAIN-1 protocol is a close match: the 36 mg arm moved through 1, 3, 6, 12 and 24 mg at 4 week intervals, so it reached 36 mg at week 21.[7] Those capsule steps correspond to 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg tablets.[2]

Trial capsule doses and Foundayo tablet doses
This is the single most useful table on the page. Lilly Medical Information maps each trial capsule strength to the approved tablet, and says plainly that capsules and tablets are not substitutable milligram for milligram. Tablet strengths run numerically lower, especially at higher doses, because of differences in absorption.[2] A Phase 1 study of 429 adults found the capsule and its dose-adjusted tablet bioequivalent at all six strengths after 7 days of fasted dosing.[12] Only tablets are approved and available in the United States.[2]
Swipe the table sideways to see every column.
| Trial capsule | Foundayo tablet | Tablet number as a share of capsule number | Where the capsule dose appears |
|---|---|---|---|
| 1 mg | 0.8 mg | 80% | Starting step in the ATTAIN-1 protocol[2][7] |
| 3 mg | 2.5 mg | 83% | Escalation step in ATTAIN-1; fixed-dose arm in ACHIEVE-1, -2, -5, -J and Phase 2 diabetes[7][10][13][14][17][18] |
| 6 mg | 5.5 mg | 92% | Fixed-dose arm in ATTAIN-1 and ATTAIN-2[5][6] |
| 12 mg | 9 mg | 75% | Fixed-dose arm in ATTAIN, ACHIEVE and both Phase 2 trials[5][6][8][10][13][15] |
| 24 mg | 14.5 mg | 60% | Phase 2 arm; escalation step on the way to 36 mg in ATTAIN-1[7][8][10] |
| 36 mg | 17.2 mg | 48% | Top fixed-dose arm in every Phase 3 trial that used one[5][6][13][15] |
| 45 mg | No equivalent in Lilly’s table | Not mapped | Phase 2 arms only[2][8][10] |
The share column is arithmetic on Lilly’s table (for example 17.2 divided by 36). The 24 mg capsule (14.5 mg tablet) was a Phase 2 arm and an allowed maximum tolerated dose in ATTAIN-MAINTAIN, but it was not a fixed-dose arm in any Phase 3 trial I read; those arms were 6, 12 and 36 mg in obesity and 3, 12 and 36 mg in diabetes.[5][6][8][13][14][20]
ATTAIN-1: the dose-response trial in obesity
ATTAIN-1 randomized 3,127 adults with obesity, or overweight plus a weight-related condition, and no diabetes, to 6, 12 or 36 mg capsules or placebo in a 3:3:3:4 ratio, for 72 weeks, alongside a healthy diet and physical activity.[5][7] Mean starting weight was 103.2 kg and mean BMI 37.[1] The primary result uses the treatment-regimen estimand, which counts everyone as randomized, including people who stopped the drug.[5]
Swipe the table sideways to see every column.
| Arm (capsule, tablet equivalent) | Journal: mean loss (95% CI) | Label: mean loss | Lost 5% or more (label) | Lost 10% or more (label) | Lost 15% or more (label) | Lost 20% or more (label) | Stopped for side effects (Lilly topline) |
|---|---|---|---|---|---|---|---|
| 6 mg capsule, 5.5 mg tablet | 7.5% (6.8 to 8.2) | 7.4% | 59.6% | 32.5% | 14.3% | 5.9% | 5.1% |
| 12 mg capsule, 9 mg tablet | 8.4% (7.7 to 9.1) | 8.3% | 63.1% | 39.8% | 20.1% | 8.9% | 7.7% |
| 36 mg capsule, 17.2 mg tablet | 11.2% (10.4 to 12.0) | 11.1% | 71.5% | 54.5% | 35.9% | 18.4% | 10.3% |
| Placebo | 2.1% (1.4 to 2.8) | 2.1% | 26.8% | 13% | 6% | 2.9% | 2.6% |
Sources: journal abstract,[5] label,[1] Lilly topline release.[7] Journal and label describe the same trial and estimand, and differ by a tenth of a point because the label analysis names modified multiple imputation for missing data and the abstract does not state its method. Lilly’s own approval release quotes 11.1% for the top dose.[3] On the efficacy estimand, which counts only time on treatment, Lilly reported 7.8%, 9.3% and 12.4% loss against 0.9% on placebo.[7]
What the dose response shows
Weight loss rose with dose, and the steps were uneven. Going from the 6 mg to the 12 mg capsule arm added 0.9 percentage points of average loss. Going from 12 to 36 mg added 2.8 more.[5] The threshold numbers tell the same story: 54.5% of people on the top tablet-equivalent lost 10% or more, against 39.8% and 32.5% on the lower two.[1] These are group averages, not a forecast for any one person. The Atlas trial results explorer shows these curves in pounds.
ATTAIN-2: obesity with type 2 diabetes
ATTAIN-2 ran 72 weeks in 1,613 adults with a BMI of 27 or higher and HbA1c between 7% and 10%. Randomization was 1:1:1:2 to 6, 12 or 36 mg capsules or placebo.[6] Baseline weight was 101.4 kg and baseline HbA1c about 8%.[1][6] Across the two trials, people with type 2 diabetes lost less at every dose (5.1% to 9.6%) than people without it (7.5% to 11.2%).[5][6]
Swipe the table sideways to see every column.
| Arm (capsule, tablet equivalent) | Journal: mean loss (95% CI) | Journal: difference from placebo | Label: mean loss | Label: HbA1c change | Lost 10% or more (label) |
|---|---|---|---|---|---|
| 6 mg capsule, 5.5 mg tablet | 5.1% (4.2 to 6.0) | 2.7 points (1.6 to 3.7) | 5.1% | 1.2 points lower | 22.5% |
| 12 mg capsule, 9 mg tablet | 7.0% (6.2 to 7.8) | 4.5 points (3.6 to 5.5) | 7.0% | 1.4 points lower | 31.1% |
| 36 mg capsule, 17.2 mg tablet | 9.6% (8.7 to 10.5) | 7.1 points (6.1 to 8.2) | 9.6% | 1.7 points lower | 45.6% |
| Placebo | 2.5% (1.9 to 3.0) | Not applicable | 2.5% | 0.4 points lower | 9.2% |
Journal figures use the treatment-regimen estimand.[6] Label figures are from Trial 2.[1] Adverse-event discontinuations were 6.1 to 9.9% on orforglipron against 4.1% on placebo.[6] The steps between doses here were 1.9 and 2.6 percentage points, so the dose response was steadier than in ATTAIN-1.
The ACHIEVE program in type 2 diabetes
The ACHIEVE trials tested 3, 12 and 36 mg capsules against placebo, dapagliflozin, oral semaglutide and insulin glargine. They matter for dosing because they show how the same three strengths behave in a different population, but Foundayo is not labeled for diabetes in the United States.[1]
Swipe the table sideways to see every column.
| Trial | Arms (capsule mg) | Duration | HbA1c change | Weight change | Basis |
|---|---|---|---|---|---|
| ACHIEVE-1[13] | 3, 12, 36 vs placebo | 40 weeks | 1.24, 1.47, 1.48 lower vs 0.41 lower | 4.5%, 5.8%, 7.6% loss vs 1.7% | Estimated mean change; estimand not named in the abstract |
| ACHIEVE-2[14] | 3, 12, 36 vs dapagliflozin 10 mg | 40 weeks | 1.23, 1.50, 1.56 lower vs 0.81 lower | Not in abstract | Treatment-regimen; non-inferior, differences of 0.42, 0.70 and 0.75 points |
| ACHIEVE-3[15] | 12, 36 vs oral semaglutide 7 and 14 mg | 52 weeks | 1.71 and 1.91 lower vs 1.23 and 1.47 lower | Not in abstract | Treatment-regimen; both orforglipron doses superior |
| ACHIEVE-4[16][21] | Maximum tolerated dose up to 36 vs insulin glargine | Median 2 years | Lilly: 1.6 vs 1.0 lower at 52 weeks | Lilly: 8.8% loss vs 1.7% gain at 52 weeks | Safety trial; cardiovascular events 4.2% vs 5.0%, hazard ratio 0.84 (0.59 to 1.20) |
| ACHIEVE-5[17] | 3, 12, 36 vs placebo, added to insulin glargine | 40 weeks | 1.58, 1.88, 1.82 lower vs 0.79 lower | 2.6%, 4.8%, 5.4% loss vs 0.2% gain | Estimated mean change; estimand not named in the abstract |
| ACHIEVE-J[18] | 3, 12, 36 (Japan) | 52 weeks | Not in abstract | Not in abstract | Safety primary; AE discontinuations 5%, 8%, 14% |
In ACHIEVE-3 the pulse rose 3.7 beats per minute on 12 mg and 4.7 on 36 mg, against 1.0 and 1.5 on semaglutide 7 and 14 mg.[15] Lilly reports ACHIEVE-4 dosing in tablet-equivalent terms: start at 0.8 mg, raise every four weeks, up to the maximum tolerated dose, capped at 17.2 mg.[16][21]
Phase 1 and Phase 2: where the dose range came from
Swipe the table sideways to see every column.
| Study | Doses (capsule unless stated) | Duration | What it found |
|---|---|---|---|
| Phase 1a, 92 healthy adults[11] | Single 0.3 to 6 mg; daily with weekly escalation to final targets of 2 to 24 mg | Single dose; 4 weeks | Roughly dose-proportional exposure. Half-life 24.6 to 35.3 hours after one dose and 48.1 to 67.5 hours on day 28. Weight down up to 5.4 kg vs 2.4 kg on placebo after 4 weeks. Gastric emptying delayed on day 28. |
| Phase 2 obesity, 272 adults[8][9] | 12, 24, 36, 45 mg | 36 weeks | Week 36 loss ranged from 9.4% to 14.7% vs 2.3% on placebo (efficacy estimand, per Lilly). Lost 10% or more: 47%, 62%, 75% and 69% on 12, 24, 36 and 45 mg vs 9%. Stopped for side effects: 10 to 17% across doses. |
| Phase 2 type 2 diabetes, 383 adults[10] | 3, 12, 24, 36 (two escalation regimens), 45 (two regimens) | 26 weeks | HbA1c fell up to 2.10 points (1.67 beyond placebo) vs 0.43 on placebo and 1.10 on dulaglutide. Weight fell up to 10.1 kg vs 2.2 kg on placebo. Doses of 12 mg and above beat placebo and dulaglutide on both measures. |
One detail stands out. In the Phase 2 obesity trial the 45 mg arm did not beat the 36 mg arm on the share of people losing 10% or more (69% against 75%).[9] The arms were small and the trial was not built to rank doses against each other, so this is a hint that the dose curve flattens near the top. Treat it as a hint, not a finding.
Pharmacokinetics: half-life, timing and food
Swipe the table sideways to see every column.
| Property | Value | Source |
|---|---|---|
| Half-life | About 29 to 49 hours after an oral dose (label). Phase 1 reported 24.6 to 35.3 hours after a single dose and 48.1 to 67.5 hours on day 28.[1][11] | Prescribing information (label); Published human clinical trial (Tier 1) |
| Time to peak | 4 to 8 hours after dosing[1] | Prescribing information (label) |
| Bioavailability | 77% (geometric mean) after a 0.8 mg dose[1] | Prescribing information (label) |
| Steady state | After about 1 week of once-daily dosing[1] | Prescribing information (label) |
| Food | No clinically relevant effect. With an investigational 37.5 mg tablet, a meal lowered AUC by 19% and peak concentration by 26%, with time to peak and half-life unchanged.[1] | Prescribing information (label) |
| Metabolism and exit | Mainly liver CYP3A4. After a single 2.5 mg dose, 87% was recovered in feces and under 1% in urine.[1] | Prescribing information (label) |
| Interaction extremes | Clarithromycin raised exposure 3.5-fold; carbamazepine lowered it 82%[1] | Prescribing information (label) |
| Stomach emptying | Delayed, most after the first dose, and the delay lessens with time[1] | Prescribing information (label) |
Steady state arrives in about a week, yet the label asks for at least 30 days per step. The label does not give a reason. Most gastrointestinal events in the trials came during dose escalation,[6][8][13] so the longer wait is best read as a tolerability measure rather than a pharmacokinetic need. That is my reading, not a statement from the label.
Switching from injections: ATTAIN-MAINTAIN
ATTAIN-MAINTAIN is the nearest thing to a conversion study. It randomized 376 adults who had lost weight on tirzepatide (205) or semaglutide (171) in SURMOUNT-5 to orforglipron or placebo for 52 weeks.[19] Among people who reached a weight plateau, those on orforglipron kept an estimated 74.7% of their prior weight reduction after tirzepatide and 79.3% after semaglutide, against 49.2% and 37.6% on placebo (treatment-regimen estimand).[19] Lilly reports that participants began at 12 mg and stepped up every 4 weeks to a maximum tolerated 24 or 36 mg capsule. Neither the label nor the paper gives a rule for converting an injectable dose into an orforglipron dose.[1][19][20]
Sleep apnea trial, announced 9 November 2026. In ATTAIN-OSA (NCT06649045), 712 adults with moderate-to-severe obstructive sleep apnea and obesity or overweight took oral orforglipron or placebo for 52 weeks. Escalation started at 0.8 mg once daily and increased every four weeks to a maximum tolerated 9, 14.5 or 17.2 mg. Apnea-hypopnea events per hour fell by 21.1 against 4.3 on placebo in the group without CPAP (363 people), and by 18.3 against 5.5 in the group using CPAP (349 people), on the efficacy estimand. Source: Lilly press release, 9 November 2026 (sponsor reported; the paper had not been read for this update).
Animal research amounts
The discovery paper describes orforglipron (then LY3502970) as a partial agonist at the GLP-1 receptor, biased toward G protein signaling over beta-arrestin recruitment, and as binding a site that involves a primate-specific amino acid, which the authors say informs its species selectivity.[22] Oral dosing lowered glucose in mice engineered to carry the human GLP-1 receptor and reduced food intake in nonhuman primates, with effects comparable to injected exenatide.[22] The abstracts give no milligram per kilogram figures.
Swipe the table sideways to see every column.
| Species or model | Amount | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|
| Mice with the human GLP-1 receptor; nonhuman primates | Not stated in the abstract | Not stated | Not stated | Oral | Published animal research (Tier 3)[22] |
| Humanized GLP-1 receptor mice, lean and diet-induced obese; wild-type mice | Not stated in the abstract | Not stated | Chronic dosing in obese mice | Not stated | Published animal research (Tier 3). Inactive in wild-type mice.[23] |
| Rats and mice (label statement) | Not applicable | Not applicable | Not applicable | Not applicable | Prescribing information (label): not pharmacologically active in rats or mice[1] |
Animal amounts do not translate into human doses, so none are converted here. Anyone quoting a “mouse dose scaled to humans” for orforglipron is doing a calculation no source on this page supports, and for ordinary mice the drug does not even work.
Vial, powder and counterfeit offers
This is the material many people are really searching for when they type “orforglipron dosage,” “orforglipron vial” or “orforglipron 6 mg.” None of it is clinical evidence. The first thing to know is the route: the label, every trial and Lilly’s own product pages describe a drug swallowed as a tablet or capsule, and I found no source describing an injectable orforglipron product or any human data on an injected or dissolved powder.[1][2]
The milligram trap
Trial papers say 36 mg. The label says 17.2 mg. Both describe the same dose step; the difference is formulation, because the tablet absorbs differently from the trial capsule.[2] A reader who takes “36 mg” from a paper and applies it to anything else is working with a number that was never a Foundayo dose. A reader who sees a 6 mg or 12 mg “research dose” on a calculator is looking at a capsule arm from ATTAIN-1, where the tablet equivalents are 5.5 and 9 mg.[2][5] The calculator pages that go further, by pairing those trial numbers with a subcutaneous route, combine a number from one formulation with a route that no study has tested.
What each source says
Swipe the table sideways to see every column.
| Reported protocol | Amount reported | Frequency | Duration | Route | Source type | Source |
|---|---|---|---|---|---|---|
| Wiki 30 mg vial calculator | 30 mg vial (10 and 15 mg also listed) with 2 mL bacteriostatic water gives 15 mg/mL; default dose 6 mg is 0.4 mL or 40 units; “research range” 6 to 12 mg; chart of 3, 6, 9 and 12 mg | Once daily | Reconstituted vial “generally” used within 28 days | Subcutaneous (calculator); the same page calls the drug an oral capsule needing no mixing | Community reported (Tier 6); cites trial names, no papers | Peptide wiki[31] |
| Wiki 10 mg vial calculator | 10 mg vial with 2 mL water gives 5 mg/mL; 6 mg is 1.2 mL or 120 units | Once daily | Same 28 day statement | Subcutaneous (calculator) | Community reported (Tier 6); origin unclear | Peptide wiki[32] |
| Wiki dosing protocols page | Repeats trial arms 6, 12 and 36 mg and Phase 2 12 to 45 mg; no titration schedule; “no missed-dose guidance”; calls the drug not FDA approved | Once daily | “Ongoing” | Oral capsule (this page) | Community reported (Tier 6); page dated February 2026, before approval | Peptide wiki[30] |
| Wiki community reports page | None. Anecdotal report count shown as zero; sources are two subreddit home pages | Not stated | Not stated | Not stated | Community reported (Tier 6); empty | Peptide wiki[33] |
| “Research use only” seller overviews | None. States that concentrations, volumes and quantities are “deliberately not given” | Not stated | Not stated | Not stated (page describes an oral drug) | Vendor reported (Tier 6); seller not named here | Seller pages[34] |
| Counterfeit pharmacy site | Four “doses” offered: 3, 12, 24 and 36 mg, all marked backordered, $200 per order, ordering through a messaging app | Not stated | Not stated | Not stated | Vendor reported (Tier 6); described as counterfeit by the reporting firm | Domain-intelligence report[29] |
The wiki pages contradict themselves. The 10 mg calculator asks for 120 units from a vial mixed with 2 mL, which cannot be drawn into a standard 100-unit, 1 mL insulin syringe.[32] Both calculators say the drug is a capsule taken whole and also give subcutaneous injection steps.[31][32] The protocols page says no missed-dose guidance exists; the label now has some.[1][30] The page also gives 29.9% of people losing 10% or more at 6 mg, a figure that matches nothing in the Lilly release, which reports 33.3% on the treatment-regimen estimand and 35.9% on the efficacy estimand.[7][30] Treat these as descriptions of what circulates, not as protocols.
Counterfeit offers, with trial-capsule numbers
A May 2026 news report on an analysis by WhoisXML API said that a counterfeit pharmacy site selling “orforglipron” existed well before approval, listing 3, 12, 24 and 36 mg at $200 per order with orders taken over a messaging app.[29] The same report counted 172 domains containing “Foundayo” in zone files within a week of launch, of which about 58 appeared to belong to Lilly.[29] The strengths on that site are trial capsule numbers, not label tablet numbers, which suggests the offer was built from the papers rather than the label.[29]
Why vial math does not rescue any of this
For approved injectables the unit calculation rests on a labeled concentration. Here there is no approved vial, no labeled concentration, and no pharmacokinetic study of the drug given by injection or from a raw powder. A calculator can divide milligrams by milliliters correctly and still describe a dose nobody has measured. The units guide explains the arithmetic with no preset dose, and the guide to injected, oral and nasal routes covers why a small molecule can be a pill when a peptide usually cannot. Orforglipron is a small molecule, so peptide reconstitution advice does not carry over.[5][22]
Escalation, timing, duration and routes

- Route: oral tablet. The label lists no other form, and Lilly says only tablets are approved and available in the United States.[1][2]
- Frequency and timing: once daily, with or without food, at any time of day; the label reports no clinically relevant food effect.[1][3]
- Why daily: the label reports a half-life of about 29 to 49 hours, peak levels at 4 to 8 hours and steady state after about a week.[1]
- Duration: the label says to maintain weight reduction long term. The longest placebo-controlled weight data are 72 weeks.[1][5][6] The ATTAIN-1 registry record lists a further 2 years of follow-up for participants who had prediabetes, with completion registered for October 2027.[24]
- Dose reduction: the label requires a lower restart dose after 7 or more consecutive missed doses.[1] Lilly says trial dose reductions were allowed only for gastrointestinal tolerability, and only after other measures failed.[7]
- Stopping: I found no randomized orforglipron withdrawal trial. ATTAIN-MAINTAIN tested switching to orforglipron from injectables, not stopping it.[19]
- Switching products: neither the label nor the papers give a conversion from semaglutide or tirzepatide doses.[1][19] The Atlas page on the Wegovy pill covers the other oral option.
Interactions, organs and contraception
Swipe the table sideways to see every column.
| Situation | What the label says |
|---|---|
| Strong CYP3A4 inhibitor | Cap at 9 mg a day; avoid inhibitors that also block OATP1B, such as ritonavir[1] |
| Strong or moderate CYP3A4 inducer | Avoid strong inducers; with moderate inducers monitor effectiveness and escalate as needed[1] |
| Simvastatin | Do not exceed 20 mg once daily[1] |
| Insulin or a sulfonylurea | Consider lowering their dose when starting, because of low blood sugar risk[1] |
| Oral birth control | Switch to a non-oral method or add a barrier method for 30 days after starting and after each dose escalation[1] |
| Other oral medicines | Delayed stomach emptying may change their absorption[1] |
| Kidney impairment | No dose adjustment; monitor kidney function if vomiting or diarrhea could cause dehydration[1] |
| Liver impairment | No change for mild or moderate; not recommended in severe[1] |
| Age under 18 | Safety and effectiveness not established[1] |
Combinations and stacks
Swipe the table sideways to see every column.
| Category | Combination | What exists |
|---|---|---|
| Formally studied | With metformin background therapy | ACHIEVE-2 and ACHIEVE-3 enrolled adults on metformin[14][15] |
| Formally studied | Added to titrated insulin glargine | ACHIEVE-5, 40 weeks[17] |
| Formally studied | After injectable tirzepatide or semaglutide | ATTAIN-MAINTAIN, 52 weeks[19] |
| Labeled caution | Any other GLP-1 receptor agonist | The label says concomitant use is not recommended[1] |
| Labeled caution | Insulin, sulfonylureas, simvastatin, CYP3A4 drugs | Dose rules in the table above[1] |
| Practitioner reported | Not identified | No practitioner source with orforglipron combination amounts was found |
| Community reported | Peptide “stacks” with orforglipron | No dosing source meeting this site’s standard was identified |
Side effects, quality and sourcing risks
Side effects track the dose and are mostly digestive. The label’s pooled table for the two obesity trials is below. Percentages are the share of patients with each reaction.[1]
Swipe the table sideways to see every column.
| Reaction | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Dyspepsia | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
| Fatigue | 4% | 6% | 7% | 9% |
| Hair loss | 2% | 4% | 4% | 5% |
Group sizes were 1,576 on placebo and 1,051, 1,055 and 1,049 on 5.5, 9 and 17.2 mg.[1] Headache, abdominal distension, belching, reflux and flatulence also reached 5% or more.[1]
In the same pooled data, 8% of treated patients stopped for adverse reactions (6%, 9% and 10% on 5.5, 9 and 17.2 mg) against 3% on placebo, and most stops were gastrointestinal.[1] Mean heart rate rose 4 to 5 beats per minute against 0.5 on placebo, and tachycardia was reported in 3% against 0.9%.[1] Severe gastrointestinal reactions occurred in about 3% against 1% on placebo, and acute pancreatitis was confirmed in 6 treated patients and 1 on placebo.[1] The label carries a boxed warning on thyroid C-cell tumors, with a contraindication for a personal or family history of medullary thyroid carcinoma or MEN 2.[1] A pooled liver-safety analysis of seven Phase 3 trials (6,920 orforglipron participants) found no cases consistent with drug-induced liver injury.[37] The Atlas covers timing in its week-by-week side effects page.
Against oral semaglutide in ACHIEVE-3, orforglipron had more stomach events (58% to 59% against 37% to 45%) and more stops for side effects (9% and 10% against 4% and 5%).[15] Against insulin glargine in ACHIEVE-4, stomach events were 62.1% against 14.2%, while clinically significant low blood sugar was 6.8% against 19.2%.[16]
Quality risks apply to anything not made under the approval. A powder or capsule sold as “research use only” carries no label strength, no approved concentration and no assurance that the contents match the name. A seller’s certificate of analysis is the seller’s own claim; the guide to reading a COA explains what it can and cannot show. FDA’s 1 October 2026 page on unapproved GLP-1 drugs says companies have been warned for selling products labeled for research or “not for human consumption” with dosing instructions. It does not name orforglipron, but it describes the same practice.[28]
Regulatory and development status
As of 2 November 2026, FDA approved Foundayo on 1 April 2026 for weight management in adults, and the label carries 2026 as the initial approval year.[1][3][4] Lilly opened prescriptions through its self-pay channel at once, with retail pharmacy shipping by 9 April, and lists self-pay from $149 a month for the lowest dose; the Atlas keeps a cost tool and a dated price ledger for current prices.[3][4]
Type 2 diabetes is not an approved U.S. use. Lilly has submitted orforglipron to FDA for it, with no public decision date, and has filed in more than 40 countries.[27] In Europe the advisory committee (CHMP) adopted a positive opinion on 15 October 2026 for weight management and type 2 diabetes, with the European Commission decision still to come when that was reported.[25] Trade press reports the UK MHRA authorised Foundayo on 10 August 2026.[26] The Atlas tracks the U.S. position on its Foundayo brand page and orforglipron medication page.
Unapproved orforglipron: the only approved U.S. form is the tablet, and Lilly says the capsules used in the trials are not approved or available here.[2] I found no approved vial, injectable or raw-powder product. A March 2026 newsletter asserted that orforglipron “cannot be compounded under current FDA rules” without citing a rule, and a 28 April 2026 legal analysis said only that FDA may be less tolerant of compounded alternatives as more approved oral options arrive.[35][36] I found no FDA statement about compounded or research-labeled orforglipron, and silence is not permission. It also sits outside the peptide compounding debate in our HHS peptide policy post, because it is a small molecule rather than a peptide. For the peptide drugs in the class, see semaglutide and tirzepatide.
What is not public
- Any human pharmacokinetic or safety data for orforglipron given by injection, dissolved from a powder, or taken as an unformulated research chemical. None was identified.[12][30]
- A Phase 3 result above the 36 mg capsule (17.2 mg tablet). The 45 mg capsule exists only in Phase 2, and Lilly’s mapping table has no tablet for it.[2][8]
- The per-dose weight results of the Phase 2 obesity trial at 24 and 36 mg. The sources I could open give only the range and the share losing 10% or more.[8][9]
- The reason for the 30 day minimum per step, and criteria for choosing among 9, 14.5 and 17.2 mg. The label sections I read name only response and tolerability.[1]
- A conversion between orforglipron doses and semaglutide, tirzepatide or any other GLP-1 dose. No label or trial supplies one.[1][19]
- What happens to weight after stopping orforglipron. ATTAIN-1 has a registered extension, but no result for it was in the sources I opened.[24]
- The content, purity or true strength of any given research vial or capsule. Only a lab test of that item could say.
Frequently asked questions
What is the Foundayo (orforglipron) dosage?
On the FDA label, Foundayo starts at 0.8 mg once daily. After at least 30 days it goes to 2.5 mg, then 5.5 mg after at least 30 more, and then to 9, 14.5 or 17.2 mg based on response and tolerability, with at least 30 days on each step. The maximum is 17.2 mg once daily.[1]
What is the orforglipron dose chart?
It is the label ladder: 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg once daily. Using every strength and holding each for the 30 day minimum puts the first day on each at day 1, 31, 61, 91, 121 and 151. The label sets a minimum interval, not a required timetable.[1]
Why do the trials say 36 mg when the highest Foundayo tablet is 17.2 mg?
The trials used capsules, and the approved product is a tablet. Lilly maps the 36 mg capsule to the 17.2 mg tablet, and says capsules and tablets are not substitutable milligram for milligram. A Phase 1 study found each capsule and its dose-adjusted tablet bioequivalent.[2][12]
Is a 12 mg orforglipron dose the same as a 9 mg Foundayo tablet?
Lilly maps the 12 mg trial capsule to the 9 mg tablet. The full map is 1 to 0.8, 3 to 2.5, 6 to 5.5, 12 to 9, 24 to 14.5 and 36 to 17.2 mg. Tablet numbers are lower, especially at higher doses, because of absorption differences.[2]
How long do you stay on each Foundayo dose?
At least 30 days on the current dose before each increase, according to the label. The label names no upper limit on time at a dose. The ATTAIN trials used 4 week steps with capsule equivalents of the same ladder.[1][7]
Is Foundayo dosed by body weight?
No. The label uses fixed milligram strengths with no milligram-per-kilogram rule, and the trials gave the same capsule doses to every participant in an arm.[1][5]
Can you take Foundayo with food, and what if you miss a dose?
The label says to take it once daily with or without food and to swallow it whole. A missed dose should be taken as soon as possible without doubling the next one. After 7 or more consecutive missed doses, escalation restarts at a lower dosage.[1]
How much weight did people lose at each orforglipron dose?
In ATTAIN-1 (adults without diabetes, 72 weeks, treatment-regimen estimand), average loss was 7.5%, 8.4% and 11.2% on the 6, 12 and 36 mg capsules, against 2.1% on placebo. In ATTAIN-2 (with type 2 diabetes) it was 5.1%, 7.0% and 9.6% against 2.5%.[5][6]
Is there an injectable or vial form of orforglipron, and is it legal?
No approved vial or injectable exists. The label and every trial describe an oral drug, and only tablets are approved in the United States. Calculator pages that give subcutaneous orforglipron doses cite no study, and no human data on an injected form were identified.[1][2][31]
Bottom line
Orforglipron dosing has an unusual split: a clean label ladder and a set of trial numbers that look different for the same steps. What is genuinely published: a label schedule from 0.8 to 17.2 mg once daily with at least 30 days per step, and randomized evidence for 6, 12 and 36 mg capsules (5.5, 9 and 17.2 mg tablets) over 72 weeks, with weight loss of 7.5%, 8.4% and 11.2% in ATTAIN-1.[1][2][5] What is merely reported online: a 6 mg once-daily subcutaneous vial protocol and a 6 to 12 mg “research range,” with no reference list and an internal contradiction about the route.[30][31][32] What is speculative: any amount above the 36 mg capsule, and anything about injected or powdered orforglipron, where no human data exist.[2][8] The biggest practical hazard is the unit mix-up. A trial capsule milligram, a label tablet milligram and an unmeasured vial milligram are three different things, and a counterfeit offer built from trial numbers shows how easily they get confused.[2][29]
Keep reading
Sources
- Eli Lilly and Company. FOUNDAYO (orforglipron) tablets prescribing information. Revised 7/2026. https://uspl.lilly.com/foundayo/foundayo.html Prescribing information (label)
- Lilly Medical Information. Why are the approved doses of Foundayo (orforglipron) different from the doses studied in clinical trials? Date of last review 19 August 2026. https://medical.lilly.com/us/products/answers/why-are-the-approved-doses-of-foundayo-orforglipron-different-from-the-doses-studied-in-clinical-trials-367128 Maker page
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. News release, 1 April 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill Company announcement (sponsor-reported, not peer reviewed)
- Eli Lilly and Company. Foundayo (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. News release, 9 April 2026. https://investor.lilly.com/news-releases/news-release-details/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-weight-loss Company announcement
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774 PMID 40960239. NCT05869903. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2). Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8 PMID 41275875. NCT05872620. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity. News release, 7 August 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273 Company announcement (sponsor-reported, not peer reviewed)
- Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. https://doi.org/10.1056/NEJMoa2302392 PMID 37351564. NCT05051579. Published human clinical trial (Tier 1). Phase 2. Funded by Eli Lilly.
- Eli Lilly and Company. Lilly’s phase 2 results published in the New England Journal of Medicine show orforglipron achieved up to 14.7% mean weight reduction at 36 weeks. News release, 23 June 2023. https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine Company announcement; source of per-dose 10% responder rates and efficacy-estimand label
- Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472-483. https://doi.org/10.1016/S0140-6736(23)01302-8 PMID 37369232. NCT05048719. Published human clinical trial (Tier 1). Phase 2. Funded by Eli Lilly.
- Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants. Diabetes Obes Metab. 2023;25(9):2634-2641. https://doi.org/10.1111/dom.15184 PMID 37344954. Published human clinical trial (Tier 1). Phase 1. Authors are Eli Lilly employees.
- Ma X, Li YG, Raha S, et al. Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight. Diabetes Obes Metab. 2026;28(7):5803-5809. https://doi.org/10.1111/dom.70783 PMID 41994902. NCT06440980. Published human clinical trial (Tier 1). Phase 1. Authors are Eli Lilly employees.
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025;393(11):1065-1076. https://doi.org/10.1056/NEJMoa2505669 PMID 40544435. NCT05971940. Published human clinical trial (Tier 1). Funded by Eli Lilly.
- Welch M, Forst T, Jia W, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2). Lancet. 2026;408(10550):125-140. https://doi.org/10.1016/S0140-6736(26)00800-7 PMID 42259339. NCT06192108. Published human clinical trial (Tier 1). Open label, orforglipron dose-blinded.
- Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026;407(10534):1147-1160. https://doi.org/10.1016/S0140-6736(26)00202-3 PMID 41765029. NCT06045221. Published human clinical trial (Tier 1). Open label.
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4). Lancet. 2026;408(10564):1557-1570. https://doi.org/10.1016/S0140-6736(26)01865-9 PMID 42815506. NCT05803421. Published human clinical trial (Tier 1). Open label, event driven.
- Giorgino F, D’Souza S, Ludwig L, et al. Orforglipron added to titrated insulin glargine in type 2 diabetes: the ACHIEVE-5 randomized clinical trial. JAMA. 2026;336(5):389-399. https://doi.org/10.1001/jama.2026.9512 PMID 42251769. NCT06109311. Published human clinical trial (Tier 1).
- Yabe D, Shiraiwa T, Ugai H, et al. Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J). Lancet Diabetes Endocrinol. 2026;14(10):841-855. https://doi.org/10.1016/S2213-8587(26)00138-5 PMID 42607698. NCT06010004. Published human clinical trial (Tier 1). Open label.
- Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. https://doi.org/10.1038/s41591-026-04386-7 PMID 42120723. NCT06584916. Published human clinical trial (Tier 1).
- Eli Lilly and Company. Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial. News release, 18 December 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after Company announcement; source of the 12 mg start and the 24 or 36 mg maximum
- Eli Lilly and Company. Lilly’s oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study. News release, 30 September 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-foundayo-orforglipron-demonstrated Company announcement (sponsor-reported, not peer reviewed)
- Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959-29967. https://doi.org/10.1073/pnas.2014879117 PMID 33177239. Published animal research (Tier 3) and laboratory research (Tier 4)
- Sonne N, Roque M, Zachariassen LF, et al. Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development. EBioMedicine. 2026;124:106121. https://doi.org/10.1016/j.ebiom.2026.106121 PMID 41547115. Published animal research (Tier 3). Funded by two companies other than the originator.
- ClinicalTrials.gov. NCT05869903: A study of orforglipron (LY3502970) in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1). Sponsor: Eli Lilly. https://clinicaltrials.gov/study/NCT05869903 Registered human trial (Tier 2). Results posted; extension for participants with prediabetes.
- European Medicines Agency. Foundayo (orforglipron): CHMP positive opinion, meeting of 12 to 15 October 2026. https://www.ema.europa.eu/is/node/288002 Regulator page
- Pharmacy Magazine. Eli Lilly confident orders placed by UK pharmacies for Foundayo will be fulfilled. 24 August 2026. https://www.pharmacymagazine.co.uk/news/eli-lilly-confident-orders-placed-by-uk-pharmacies-for-foundayo-will-be-fulfilled Trade press report of regulator action (secondary)
- Medical Daily. Lilly files its GLP-1 pill for diabetes, and the manufacturing case is stronger than the access case. 6 August 2026. https://www.medicaldaily.com/oral-glp1-orforglipron-diabetes-filing-supply-coverage-476936 News report of company results (secondary)
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Page dated 1 October 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Regulator statement
- SecurityBrief US. Counterfeiters targeted Eli Lilly pill before launch (report by WhoisXML API). 5 May 2026. https://securitybrief.news/story/counterfeiters-targeted-eli-lilly-pill-before-launch News report of a commercial threat-intelligence analysis (secondary)
- Peptide Protocol Wiki Team. Orforglipron: dosing protocols. Page modified 12 February 2026. https://www.peptideprotocolwiki.com/peptides/orforglipron/dosing Community, vendor or clinic reported (Tier 6). No references listed; predates approval.
- Peptide Protocol Wiki Team. Orforglipron 30 mg dosing calculator. Undated. https://www.peptideprotocolwiki.com/tools/dosing-calculator/orforglipron-30mg Community, vendor or clinic reported (Tier 6); origin unclear.
- Peptide Protocol Wiki Team. Orforglipron 10 mg dosing calculator. Undated. https://www.peptideprotocolwiki.com/tools/dosing-calculator/orforglipron-10mg Community, vendor or clinic reported (Tier 6); origin unclear.
- Peptide Protocol Wiki Team. Orforglipron: community protocols and reports. Page dated 16 February 2026. https://www.peptideprotocolwiki.com/peptides/orforglipron/community Community, vendor or clinic reported (Tier 6). Shows zero reports.
- Research-chemical seller overview pages for orforglipron, updated 5 September 2026 (seller not named on purpose; address held by the editor). Vendor reported (Tier 6). Gives no amounts.
- The Dose newsletter (Buttondown). Hims folds, orforglipron can’t be compounded, India generics land March 21. 9 March 2026. https://buttondown.com/the-dose/archive/peptides-20260309/ Newsletter commentary (Tier 5 or 6); cites no rule for its compounding claim
- Lucas D. FDA approves new oral GLP-1 as scrutiny of the market intensifies. Gardner Law, via JD Supra. 28 April 2026. https://www.jdsupra.com/legalnews/fda-approves-new-oral-glp-1-as-scrutiny-5487123/ Law-firm commentary (Tier 5)
- Wharton S, Stefanski A, Chen J, et al. Hepatic safety of orforglipron in adults with obesity or overweight and/or type 2 diabetes: a pooled analysis of the orforglipron Phase 3 clinical trials. Diabetes Obes Metab. 2026;28(9):8347-8358. https://doi.org/10.1111/dom.71032 PMID 42338042. Published human clinical trial (Tier 1) (pooled analysis). Authors include Eli Lilly employees.
Educational reference only, not medical advice. This page documents amounts on prescribing information and in published and registered research, plus figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.
For a second oral small-molecule GLP-1 candidate and its trial amounts, see the ASC30 page.
For a worked example of why a pill’s headline weight loss figure depends on trial length and analysis set, with Foundayo’s 72-week trial as one yardstick, see what the CX11 11.5% weight loss figure measures.